These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27666900)

  • 1. Treatment of Type 2 Diabetes with a Breakable Extended Release Gliclazide Formulation in Primary Care: The Xrise Study.
    Mohan V; Chopra V; Sanyal D; Jain S; Jayaprakashsai J
    J Assoc Physicians India; 2015 Dec; 63(12):26-29. PubMed ID: 27666900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiologic Surveillance of Glycemic Response to a Scored, Breakable, Extended Release, Fixed Dose Combination of Gliclazide and Metformin in Persons with Type 2 Diabetes.
    Kalra S; Das AK
    J Assoc Physicians India; 2017 Jun; 65(6):38-41. PubMed ID: 28782312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar N; Zawar S; Agrawal N
    Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients.
    Lu CH; Chang CC; Chuang LM; Wang CY; Jiang YD; Wu HP
    Diabetes Obes Metab; 2006 Mar; 8(2):184-91. PubMed ID: 16448522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
    Ristic S; Collober-Maugeais C; Pecher E; Cressier F
    Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
    Zhou J; Zheng F; Guo X; Yang H; Zhang M; Tian H; Guo L; Li Q; Mo Y; Jia W
    Diabetes Metab Res Rev; 2015 Oct; 31(7):725-33. PubMed ID: 25952634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
    Ristic S; Collober-Maugeais C; Cressier F; Tang P; Pecher E
    Diabetes Obes Metab; 2007 Jul; 9(4):506-11. PubMed ID: 17587393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
    Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
    Garber AJ; Bruce S; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes.
    Zaccardi F; Jacquot E; Cortese V; Tyrer F; Seidu S; Davies MJ; Khunti K
    Diabetes Obes Metab; 2020 Dec; 22(12):2417-2426. PubMed ID: 32761768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
    Derosa G; D'Angelo A; Romano D; Maffioli P
    Drug Des Devel Ther; 2017; 11():1481-1488. PubMed ID: 28553078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ; Pans M; Rubin CJ
    Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIDDM: new once-daily intervention for type 2 diabetes mellitus: Diaprel MR.
    Ionescu-Tîrgovişte C; Gavrilă L; Brădescu OM; Guja C
    Rom J Intern Med; 2004; 42(2):431-40. PubMed ID: 15529633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study.
    Uddin MF; Khan MA; Selim S; Sultana N; Sayem MA; Iftekhar MM; Habib MB; Akter N; Khan S
    J Comp Eff Res; 2024 Feb; 13(2):e230132. PubMed ID: 38294337
    [No Abstract]   [Full Text] [Related]  

  • 17. Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination.
    Guillausseau PJ
    Diabet Med; 1997 Sep; 14(9):798-802. PubMed ID: 9300232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.
    Guillausseau PJ; Greb W
    Diabetes Metab; 2001 Apr; 27(2 Pt 1):133-7. PubMed ID: 11353879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.
    Fujioka K; Pans M; Joyal S
    Clin Ther; 2003 Feb; 25(2):515-29. PubMed ID: 12749511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
    Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
    Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.